Abstract
Background:The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy in patients with rheumatoid arthritis (RA)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have